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METHODS: A published economic simulation model of
diabetes has been modified to allow for the calculation of
the costs of glycemic management and of treating dia-
betic complications over time. Age, gender, racial compo-
sition, cardiovascular risk factors and glycemic parame-
ters were taken from a recent clinical trial in diabetic
patients. The risks of complications were derived from
epidemiological studies. Costs of management of diabetes
and its complications were based on French tariffs, pub-
lished literature, and expert opinion. A cohort of 10,000
diabetic patients was simulated for 30 years. Future costs
were discounted at 5% per year.
RESULTS: On average, the cumulative direct medical
costs of managing diabetes and treating complications ac-
crue to FFR 103,431 (€15,767) per patient. During the
first eight years, more than 50% of the total costs are at-
tributed to the treatment of macrovascular complica-
tions, stroke and myocardial infarction. Over more than
20 years, the cost of microvascular complications will
rise to over 50%, driven primarily by the cost of end-
stage renal disease. The cost of managing diabetes will re-
main at approximately 10% of the total cost throughout
the model period.
CONCLUSIONS: Treatment of macrovascular complica-
tions dominates the total cost of diabetes over the first de-
cade. Only after 20 years or more of treatment do the costs
of microvascular complications become more important.
Thus, the focus should be on efforts to reduce the risks of
stroke and myocardial infarction in these patients.
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OBJECTIVE: To quantify use of health-care resources
for management of severe hypoglycaemia.
METHODS: We defined severe hypoglycaemia as an epi-
sode of coma or seizure requiring assistance from NHS
personnel. We excluded any episodes managed exclu-
sively by persons outside the health services. We included
all patients with Type 1 or Type 2 diabetes registered
with DARTS (Diabetes Audit and Research in Tayside
Scotland) and receiving treatment with insulin or oral hy-
poglycaemic drugs from June 1, 1997 to May 31, 1998.
We identified episodes from the records of three acute-
care hospital emergency rooms, eight minor injury units
in primary-care hospitals and from Tayside Ambulance
Service records.
RESULTS: Over 150,000 records were searched to iden-
tify 295 people with one or more episodes, of which 39
were excluded because they were not residents of Tayside
and another 12 because their identity could not be reli-
ably confirmed. The incidence of major hypoglycaemia
per 100 patient years was 12.0 (95% CI 8.2-13.7) in
Type 1 diabetics, 6.8 (CI 5.2-8.9) in Type 2 diabetics tak-
ing insulin and 0.8 (CI 0.6-1.0) in Type 2 diabetics on
oral hypoglycaemics. Fifty-two patients required inpa-
tient treatment. This compares with an incidence of 2.3
per 100 patient years for patients treated with insulin in
the UKPDS trial and 5.4 in the conventional arm of the
DCCT trial. The total health-care costs were £115,541 of
which 64% was for inpatient stay, 25% for ambulance
and 11% for emergency room.
CONCLUSIONS: The incidence of hypoglycaemia was
three- to five-fold higher than previously reported in clin-
ical trials, and extrapolation of our costs suggests that
hypoglycaemia could cost the UK NHS as much as
£16.2m per year.
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OBJECTIVE: Prospective studies like UKPDS have
shown that improved glycemic control in diabetic pa-
tients can reduce the risk of micro- and macrovascular
complications. To estimate the potential savings to health-
care systems due to interventions aimed at improving gly-
cemic control, the cost of complications must be known.
The objective of this study was to assess the cost of com-
plications in type 2 diabetic patients in the Netherlands.
METHODS: A review of published literature and guide-
lines was combined with data from ongoing research
projects and expert interviews to define the management
patterns for diabetic complications. Data from detailed
cost studies were used to estimate the Event cost (i.e.,
acute and post-acute care cost in the first year) and State
cost (i.e., subsequent recurring annual cost) of complica-
tions in 2000 NLG.
RESULTS: The cost of nephropathy was dominated by
the State cost of end stage renal disease (NLG 132,692).
Event and State costs due to retinopathy were relatively
low, except for the State cost of blindness (NLG 5,000).
Lower extremity amputation costs NLG 33,683 per event
and NLG 1,148 per year for subsequent management.
The event cost for AMI and stroke were NLG 21,877
and NLG 39,867, respectively. The subsequent State
costs were estimated at NLG 4,286 and NLG 16,131.
Over a simulated 30-year time horizon, the cost due to
macrovascular complications would account for 46% of
the total cost of complications discounted at 4%.
CONCLUSION: The cost of diabetic complications in
the Netherlands is substantial. Interventions that improve
glycemic control, and moreover, that affect the incidence
